OBJECTIVES: To characterize the magnitudes of change in SALT scores corresponding to meaningful treatment benefits from the patient perspective.
METHODS: Anchor-based methods for the estimation of meaningful withinpatient change thresholds were applied to pooled data from a randomized, double-blind trial of ritlecitinib. Anchors included a patientreported measure of change in AA severity, the Patient Global Impression of Change (PGI-C), and 3 items comprising the Patient Satisfaction with Hair Growth (P-Sat) questionnaire. After reviewing Pearson correlations between change-from-baseline SALT scores and each anchor to confirm adequate association, potential thresholds were computed as mean change-from-baseline SALT scores among patients who reported moderate improvement on the PGI-C and/or moderate satisfaction on each of 3 P-Sat items at week 24.
RESULTS: 650 participants (86% adults, 14% adolescents) had mean (standard deviation) SALT scores of 90.6 (14.3) at baseline, suggesting a sample with primarily severe AA. Correlations between SALT changefrom- baseline scores and the patient-reported items supported their use as anchors. Estimates based on patients reporting moderate improvement in AA (n=102) on the PGI-C and those reporting moderate satisfaction on the P-Sat item related to the amount of hair growth at week 24 (n=122) were -42.2 (26.1) and -43.1 (26.8), respectively. Supportive estimates based on the remaining P-Sat items were similar in magnitude.
CONCLUSIONS: Among patients with severe AA, SALT change-frombaseline scores of 42 or 43 represent meaningful improvements. While the achievement of low SALT scores of ≤10 to ≤20 have been used to characterize efficacy in clinical trials, the amount of change required to meet this endpoint far exceeds the estimates in this study. The treatment goals of individual patients must be considered when evaluating benefit in both clinical trials and clinical practice.
